Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated:  8/23/2017
UNC Lineberger Comprehensive Cancer Center
344
mi
from 43215
Chapel Hill, NC
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated: 8/23/2017
UNC Lineberger Comprehensive Cancer Center
344
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated:  8/23/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
746
mi
from 43215
Tulsa, OK
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated: 8/23/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
746
mi
from 43215
Tulsa, OK
Click here to add this to my saved trials
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated:  8/23/2017
University of Pittsburgh Cancer Institute (UPCI)
166
mi
from 43215
Pittsburgh, PA
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated: 8/23/2017
University of Pittsburgh Cancer Institute (UPCI)
166
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated:  8/23/2017
Greenville Health System Cancer Institute-Faris
360
mi
from 43215
Greenville, SC
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated: 8/23/2017
Greenville Health System Cancer Institute-Faris
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated:  8/23/2017
UT Southwestern/Simmons Cancer Center-Dallas
912
mi
from 43215
Dallas, TX
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated: 8/23/2017
UT Southwestern/Simmons Cancer Center-Dallas
912
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated:  8/23/2017
Odette Cancer Centre- Sunnybrook Health Sciences Centre
316
mi
from 43215
Toronto,
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study
Status: Enrolling
Updated: 8/23/2017
Odette Cancer Centre- Sunnybrook Health Sciences Centre
316
mi
from 43215
Toronto,
Click here to add this to my saved trials
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix
Status: Enrolling
Updated:  8/23/2017
Gynecologic Oncology Group of Arizona
1662
mi
from 43215
Phoenix, AZ
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix
Status: Enrolling
Updated: 8/23/2017
Gynecologic Oncology Group of Arizona
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers
Status: Enrolling
Updated:  8/29/2017
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers
Status: Enrolling
Updated: 8/29/2017
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Hurley Medical Center
213
mi
from 43215
Flint, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Hurley Medical Center
213
mi
from 43215
Flint, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Genesys Regional Medical Center
206
mi
from 43215
Grand Blanc, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Genesys Regional Medical Center
206
mi
from 43215
Grand Blanc, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Cleveland Clinic Cancer Center at Fairview Hospital
122
mi
from 43215
Cleveland, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Cleveland Clinic Cancer Center at Fairview Hospital
122
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Pacific Gynecology Specialists
2006
mi
from 43215
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Pacific Gynecology Specialists
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Seattle Cancer Care Alliance
2006
mi
from 43215
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Seattle Cancer Care Alliance
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Green Bay Oncology Limited at Saint Mary's Hospital
404
mi
from 43215
Green Bay, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Green Bay Oncology Limited at Saint Mary's Hospital
404
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Green Bay Oncology at Saint Vincent Hospital
404
mi
from 43215
Green Bay, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Green Bay Oncology at Saint Vincent Hospital
404
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Providence Saint Joseph Medical Center-Disney Family Cancer Center
1972
mi
from 43215
Burbank, CA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Providence Saint Joseph Medical Center-Disney Family Cancer Center
1972
mi
from 43215
Burbank, CA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
1154
mi
from 43215
Aurora, CO
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Smilow Cancer Hospital Care Center at Saint Francis
553
mi
from 43215
Hartford, CT
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Smilow Cancer Hospital Care Center at Saint Francis
553
mi
from 43215
Hartford, CT
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Memorial University Medical Center
555
mi
from 43215
Savannah, GA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Memorial University Medical Center
555
mi
from 43215
Savannah, GA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Alphonsus Cancer Care Center-Boise
1715
mi
from 43215
Boise, ID
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Alphonsus Cancer Care Center-Boise
1715
mi
from 43215
Boise, ID
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Northwestern University
274
mi
from 43215
Chicago, IL
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
NorthShore University HealthSystem-Evanston Hospital
283
mi
from 43215
Evanston, IL
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
NorthShore University HealthSystem-Evanston Hospital
283
mi
from 43215
Evanston, IL
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
285
mi
from 43215
Hinsdale, IL
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
285
mi
from 43215
Hinsdale, IL
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Indiana University Melvin and Bren Simon Cancer Center
166
mi
from 43215
Indianapolis, IN
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Indiana University Melvin and Bren Simon Cancer Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Vincent Oncology Center
166
mi
from 43215
Indianapolis, IN
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Vincent Oncology Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Iowa - Holden Comprehensive Cancer Center
460
mi
from 43215
Iowa City, IA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Iowa - Holden Comprehensive Cancer Center
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Greater Baltimore Medical Center
342
mi
from 43215
Baltimore, MD
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Greater Baltimore Medical Center
342
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
349
mi
from 43215
Baltimore, MD
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
349
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Joseph Mercy Hospital
157
mi
from 43215
Ann Arbor, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Joseph Mercy Hospital
157
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Michigan Cancer Research Consortium NCORP
164
mi
from 43215
Ann Arbor, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Michigan Cancer Research Consortium NCORP
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Allegiance Health
173
mi
from 43215
Jackson, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Allegiance Health
173
mi
from 43215
Jackson, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Borgess Medical Center
206
mi
from 43215
Kalamazoo, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Borgess Medical Center
206
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Bronson Methodist Hospital
208
mi
from 43215
Kalamazoo, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Bronson Methodist Hospital
208
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
West Michigan Cancer Center
210
mi
from 43215
Kalamazoo, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
West Michigan Cancer Center
210
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Mary Mercy Hospital
168
mi
from 43215
Livonia, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Mary Mercy Hospital
168
mi
from 43215
Livonia, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Joseph Mercy Port Huron
210
mi
from 43215
Port Huron, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Joseph Mercy Port Huron
210
mi
from 43215
Port Huron, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Mississippi Medical Center
660
mi
from 43215
Jackson, MS
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Mississippi Medical Center
660
mi
from 43215
Jackson, MS
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Mercy Hospital Springfield
585
mi
from 43215
Springfield, MO
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Mercy Hospital Springfield
585
mi
from 43215
Springfield, MO
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Cox Medical Center South
587
mi
from 43215
Springfield, MO
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Cox Medical Center South
587
mi
from 43215
Springfield, MO
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Nebraska Methodist Hospital
688
mi
from 43215
Omaha, NE
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Nebraska Methodist Hospital
688
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Women's Cancer Center of Nevada
1756
mi
from 43215
Las Vegas, NV
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Women's Cancer Center of Nevada
1756
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Stony Brook University Medical Center
549
mi
from 43215
Stony Brook, NY
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Stony Brook University Medical Center
549
mi
from 43215
Stony Brook, NY
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Carolinas Medical Center / Levine Cancer Institute
348
mi
from 43215
Charlotte, NC
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Carolinas Medical Center / Levine Cancer Institute
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Carolinas HealthCare System NorthEast
341
mi
from 43215
Concord, NC
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Carolinas HealthCare System NorthEast
341
mi
from 43215
Concord, NC
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Akron General Medical Center
108
mi
from 43215
Akron, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Akron General Medical Center
108
mi
from 43215
Akron, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Case Western Reserve Univ
129
mi
from 43215
Cleveland, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Case Western Reserve Univ
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
MetroHealth Med Ctr
127
mi
from 43215
Cleveland, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
MetroHealth Med Ctr
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials